Diacerein

Diacerein is a symptomatic slow-acting drug used primarily in the management of osteoarthritis. Unlike conventional NSAIDs that mainly provide short-term pain relief, diacerein is considered to have disease-modifying potential by targeting inflammatory pathways involved in cartilage degradation. It is particularly used in patients with osteoarthritis of the knee and hip where long-term joint preservation is a therapeutic goal.

The medicine works mainly by inhibiting interleukin-1 beta (IL-1β), a pro-inflammatory cytokine that plays a significant role in cartilage breakdown and progression of osteoarthritis. By reducing IL-1 activity, diacerein helps slow cartilage degeneration while promoting synthesis of proteoglycans and other components essential for maintaining joint structure. Because of this mechanism, the onset of clinical benefit is gradual and may take several weeks of continuous therapy.

Diacerein is typically administered orally and is often recommended to be taken with meals to improve gastrointestinal tolerability. It is commonly used as part of a long-term osteoarthritis management plan that may include weight management, physiotherapy, and supportive supplements. Patients should be counseled that immediate pain relief may not occur, but sustained use may provide meaningful improvement in joint comfort and function.

The most frequently reported side effect is mild to moderate diarrhea, especially during the initial phase of therapy. Urine discoloration may also occur and is generally harmless. Liver function monitoring may be advised in long-term therapy. When prescribed appropriately and used consistently, diacerein can be a valuable component of comprehensive osteoarthritis care focused on both symptom relief and cartilage support.